Loading…
Loading…
Chronic lymphocytic leukemia is an indolent cancer of mature B lymphocytes that often needs monitoring rather than immediate treatment.
Quick Answer
Chronic lymphocytic leukemia is an indolent cancer of mature B lymphocytes that often needs monitoring rather than immediate treatment. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates chronic lymphocytic leukemia (cll) at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
CLL is the most common adult leukemia in Western populations and is increasingly recognised in Nepal. Many patients are asymptomatic at diagnosis. Treatment is indicated for progressive marrow failure, bulky or symptomatic disease, or rapid progression. Targeted therapies have changed the treatment landscape.
Diagnosis requires persistent clonal B-cell lymphocytosis confirmed by flow cytometry. FISH, TP53 sequencing and IGHV mutation status provide prognostic information. Staging and assessment of nodes, spleen and cytopenias complete the baseline.
Asymptomatic early-stage disease is observed. Treatment is considered for progressive cytopenias, bulky or symptomatic disease or rapid progression. BTK inhibitors, BCL2 inhibitors and combinations are selected according to TP53 status, comorbidity and drug interactions.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven prevention. Avoiding unnecessary immune suppression and maintaining vaccination and infection prevention are important after diagnosis.
Red flags — seek urgent care
No. Many patients with early, asymptomatic disease are monitored. Treatment is started when specific criteria are met, such as progressive marrow failure, bulky disease or symptoms.
Watch and wait means regular blood counts and clinical review without active treatment. It avoids unnecessary side effects and does not reduce the chance of responding when treatment is eventually needed.
TP53 status, IGHV mutation status, FISH and overall fitness guide the choice between targeted agents and chemoimmunotherapy. Kidney function and drug interactions also matter.
Most CLL is not inherited, but a family history is seen in a minority of patients. Relatives with persistent lymphocytosis should be evaluated.
CLL and its treatments increase the risk of bacterial, viral and fungal infections. Vaccination, prompt fever review and sometimes immunoglobulin replacement are part of care.
A small proportion of patients develop Richter transformation, an aggressive lymphoma. Sudden rapid growth, new systemic symptoms or rising LDH should be investigated promptly.
Some BTK inhibitors are continued long term, while BCL2 inhibitor-based regimens may be time-limited. The plan depends on the regimen and response.
Blood counts, clinical assessment and imaging are used, with MRD testing in selected settings. Follow-up intervals depend on disease stability.
Specialist assessment for abnormal blood counts, anaemia, low platelets, bleeding, clotting and suspected blood disorders.
Diagnosis, risk stratification and treatment planning for acute and chronic leukemias.
Immunophenotyping for leukemia, lymphoma, plasma cell disorders and cytopenias.
Non-Hodgkin lymphoma is a group of lymphoid cancers that includes indolent and aggressive subtypes.
Multiple myeloma is a cancer of plasma cells that causes bone disease, anaemia, kidney problems and immune suppression.
Myelodysplastic syndromes are clonal marrow disorders causing low blood counts and a variable risk of progression to leukemia.
Haematology
Flow Cytometry Explained: Reading the Immune Phenotype
Flow cytometry is central to diagnosing leukemia, lymphoma and plasma cell disorders. Learn what it measures and how to interpret the report.
Haematology
Molecular Testing in Blood Cancer: What the Results Mean
Cytogenetics, FISH, PCR and next-generation sequencing guide diagnosis, risk and treatment in blood cancers.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.